Fig. 1.

The design of the study and the evaluation of cognitive impairment. (A) The study design for Group A and B with time points of sevoflurane treatment, arterial blood gas analysis, MWM experiment and RNA-seq analysis. (B) MMW (training experiment on day 30–34) comparing the scape latency between groups. (C, D, E) MWM (testing experiment on day 35) comparing the average distance from original platform area, platform-crossing times and the time spent in the fourth quadrant between Group A, B and the control. (F, G) Western blot analysis of the PSD-95 levels in the hippocampus of mice collected on day 36. Quantification of Western blot is shown on the right side. “*” indicates statistical difference in all panels.